183 related articles for article (PubMed ID: 24595498)
1. In Vitro and In Situ evaluation of pH-dependence of atazanavir intestinal permeability and interactions with acid-reducing agents.
Kis O; Walmsley SL; Bendayan R
Pharm Res; 2014 Sep; 31(9):2404-19. PubMed ID: 24595498
[TBL] [Abstract][Full Text] [Related]
2. Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions.
Kis O; Zastre JA; Hoque MT; Walmsley SL; Bendayan R
Pharm Res; 2013 Apr; 30(4):1050-64. PubMed ID: 23224979
[TBL] [Abstract][Full Text] [Related]
3. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.
Zhu L; Persson A; Mahnke L; Eley T; Li T; Xu X; Agarwala S; Dragone J; Bertz R
J Clin Pharmacol; 2011 Mar; 51(3):368-77. PubMed ID: 20457590
[TBL] [Abstract][Full Text] [Related]
4. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
Yu XY; Lin SG; Zhou ZW; Chen X; Liang J; Liu PQ; Duan W; Chowbay B; Wen JY; Li CG; Zhou SF
Curr Drug Metab; 2007 May; 8(4):325-40. PubMed ID: 17504222
[TBL] [Abstract][Full Text] [Related]
5. Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract.
Robillard KR; Chan GN; Zhang G; la Porte C; Cameron W; Bendayan R
Antimicrob Agents Chemother; 2014; 58(3):1713-22. PubMed ID: 24379203
[TBL] [Abstract][Full Text] [Related]
6. Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices.
Martinec O; Huliciak M; Staud F; Cecka F; Vokral I; Cerveny L
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481446
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers.
Tomilo DL; Smith PF; Ogundele AB; Difrancesco R; Berenson CS; Eberhardt E; Bednarczyk E; Morse GD
Pharmacotherapy; 2006 Mar; 26(3):341-6. PubMed ID: 16503713
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitor therapy in atazanavir-treated patients: contraindicated?
Furtek KJ; Crum NF; Olson PE; Wallace MR
J Acquir Immune Defic Syndr; 2006 Mar; 41(3):394-6. PubMed ID: 16540945
[No Abstract] [Full Text] [Related]
9. Transepithelial permeation of tolbutamide across the human intestinal cell line, Caco-2.
Nishimura N; Naora K; Uemura T; Hirano H; Iwamoto K
Drug Metab Pharmacokinet; 2004 Feb; 19(1):48-54. PubMed ID: 15499169
[TBL] [Abstract][Full Text] [Related]
10. Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat.
Li LY; Amidon GL; Kim JS; Heimbach T; Kesisoglou F; Topliss JT; Fleisher D
J Pharmacol Exp Ther; 2002 May; 301(2):586-93. PubMed ID: 11961060
[TBL] [Abstract][Full Text] [Related]
11. Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier.
Bousquet L; Roucairol C; Hembury A; Nevers MC; Creminon C; Farinotti R; Mabondzo A
AIDS Res Hum Retroviruses; 2008 Sep; 24(9):1147-54. PubMed ID: 18729774
[TBL] [Abstract][Full Text] [Related]
12. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898
[TBL] [Abstract][Full Text] [Related]
13. Omeprazole decreases magnesium transport across Caco-2 monolayers.
Thongon N; Krishnamra N
World J Gastroenterol; 2011 Mar; 17(12):1574-83. PubMed ID: 21472124
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
Le Tiec C; Barrail A; Goujard C; Taburet AM
Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
[TBL] [Abstract][Full Text] [Related]
15. HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy.
Berginc K; Trdan T; Trontelj J; Kristl A
Biopharm Drug Dispos; 2010 Nov; 31(8-9):495-505. PubMed ID: 21104925
[TBL] [Abstract][Full Text] [Related]
16. Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity.
Lucia MB; Golotta C; Rutella S; Rastrelli E; Savarino A; Cauda R
J Acquir Immune Defic Syndr; 2005 Aug; 39(5):635-7. PubMed ID: 16044020
[No Abstract] [Full Text] [Related]
17. Intestinal absorption of forsythoside A in in situ single-pass intestinal perfusion and in vitro Caco-2 cell models.
Zhou W; Di LQ; Wang J; Shan JJ; Liu SJ; Ju WZ; Cai BC
Acta Pharmacol Sin; 2012 Aug; 33(8):1069-79. PubMed ID: 22773077
[TBL] [Abstract][Full Text] [Related]
18. Co-administration of atazanavir with proton-pump inhibitors and H2 blockers.
Khanlou H; Farthing C
J Acquir Immune Defic Syndr; 2005 Aug; 39(4):503. PubMed ID: 16010179
[No Abstract] [Full Text] [Related]
19. Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein.
Dahan A; Amidon GL
Pharm Res; 2009 Apr; 26(4):883-92. PubMed ID: 19048359
[TBL] [Abstract][Full Text] [Related]
20. Boosting of HIV protease inhibitors by ritonavir in the intestine: the relative role of cytochrome P450 and P-glycoprotein inhibition based on Caco-2 monolayers versus in situ intestinal perfusion in mice.
Holmstock N; Annaert P; Augustijns P
Drug Metab Dispos; 2012 Aug; 40(8):1473-7. PubMed ID: 22550269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
